Jubilant Organosys Limited Corporate Presentation May 2010 0 0 - PowerPoint PPT Presentation

Jubilant Organosys Limited Corporate Presentation May 2010 0 0

Disclaimer This present at ion and t he accompanying slides (t he “ Present at ion” ), which has been prepared by Jubilant Organosys Limit ed (t he "Company"), has been prepared for informat ion purposes only and is not , and is not int ended t o be, an offer, or solicit at ion of offer, or invit at ion or recommendat ion t o buy or sell any securit ies of t he Company, and shall not const it ut e an offer, solicit at ion or or invit at ion or recommendat ion t o buy or sell in any j urisdict ion in which such offer, solicit at ion or invit at ion or recommendat ion is unlawful. No part , or all, of t his Present at ion shall form t he basis of, or be relied on in connect ion wit h, any cont ract or invest ment decision in relat ion t o any securit ies of t he Company. This Present at ion is st rict ly confident ial and may not be copied, published, dist ribut ed or t ransmit t ed t o any person, in whole or in part , by any medium or in any form for any purpose. The informat ion in t his Present at ion is being provided by t he Company and is subj ect t o change wit hout not ice. This Present at ion has been prepared by t he Company based on informat ion and dat a which t he Company considers reliable, but t he Company makes no represent at ion or warrant y, express or implied, what soever, and no reliance shall be placed on, t he t rut h, accuracy, complet eness, fairness and reasonableness of t he cont ent s of t his Present at ion. This Present at ion may not be all inclusive and may not cont ain all of t he informat ion t hat you may consider mat erial. Any liabilit y in respect of t he cont ent s of, or any omission from, t his Present at ion is expressly excluded. This Present at ion cont ains st at ement s about fut ure event s and expect at ions t hat are forward-looking st at ement s. These st at ement s t ypically cont ain words such as "expect s" and "ant icipat es" and words of similar import . Any st at ement in t his Present at ion t hat is not a st at ement of hist orical fact is a forward-looking st at ement t hat involves known and unknown risks, uncert aint ies and ot her fact ors which may cause our act ual result s, performance or achievement s t o be mat erially different from any fut ure result s, performance or achievement s expressed or implied by such forward-looking st at ement s. None of t he fut ure proj ect ions, expect at ions, est imat es or prospect s in t his Present at ion should be t aken as forecast s or promises nor should t hey be t aken as implying any indicat ion, assurance or guarant ee t hat t he assumpt ions on which such fut ure proj ect ions, expect at ions, est imat es or prospect s have been prepared are correct or exhaust ive or, in t he case of t he assumpt ions, fully st at ed in t he Present at ion. The Company assumes no obligat ions t o updat e t he forward-looking st at ement s cont ained herein t o reflect act ual result s, changes in assumpt ions or changes in fact ors affect ing t hese st at ement s. You acknowledge t hat you will be solely responsible for your own assessment of t he market , t he market posit ion, t he business and financial condit ion of t he Company and t hat you will conduct your own analysis and be solely responsible for forming your own view of t he pot ent ial fut ure performance of t he business of t he Company. This Present at ion speaks as of 21 February 2010. Neit her t he delivery of t his Present at ion nor any furt her discussions of t he Company wit h any of t he recipient s shall, under any circumst ances, creat e any implicat ion t hat t here has been no change in t he affairs of t he Company since t hat dat e. This Present at ion is not being made and will not be made direct ly or indirect ly in or int o, or by use of t he mails of, or by any means or inst rument alit y of int erst at e or foreign commerce of, or any facilit ies of a nat ional securit ies exchange of, t he Unit ed S t at es. This includes, but is not limit ed t o, facsimile t ransmission, elect ronic mail, t elex, t elephone and t he Int ernet . Neit her t his Present at ion nor any copy of t his Present at ion is being, and must not be t aken or t ransmit t ed int o t he Unit ed S t at es or dist ribut ed, direct ly or indirect ly, in t he Unit ed S t at es. The informat ion present ed herein is not an offer for sale wit hin t he Unit ed S t at es of any equit y shares or ot her securit ies of t he Company. No offering of t he Company’ s securit ies is being made nor will any offering of t he Company's securit ies be regist ered under t he U.S . S ecurit ies Act of 1933, as amended (t he “ S ecurit ies Act ” ). Accordingly, unless an exempt ion from regist rat ion under t he S ecurit ies Act is available, t he Company’ s securit ies may not be offered, sold, resold, delivered or dist ribut ed, direct ly or indirect ly, int o t he Unit ed S t at es. This Present at ion is confident ial and is only addressed t o and direct ed at persons who are “ qualified invest ors” wit hin t he meaning of Art icle 2(1)(e) of t he Prospect us Direct ive (Direct ive 2003/ 71/ EC) and (i) who have professional experience in mat t ers relat ing t o invest ment s falling wit hin Art icle 19(5) of t he Financial S ervices and Market s Act 2000 (Financial Promot ion) Order 2005 (t he “ Order” ) and Art icle 49(2)(a) t o (d) of t he Order, and (ii) t o whom it may ot herwise lawfully be communicat ed (all such persons t oget her being referred t o as “ Relevant Persons” ). This Present at ion must not be act ed on or relied upon in t he Unit ed Kingdom, by persons who are not Relevant Persons. Any invest ment or invest ment act ivit y t o which t his Present at ion relat es is available only t o Relevant Persons. The dist ribut ion of t his Present at ion in cert ain j urisdict ions may be rest rict ed by law and persons int o whose possession t his Present at ion comes should inform t hemselves about and observe any such rest rict ions. 1 1

Presentation Outline Jubilant Organosys –A Snapshot Industry Overview Our Business Competitive Advantage Key Financials Growth Drivers Key Highlights 2 2

Jubilant Organosys – A S napshot Integrated pharmaceuticals outsourcing player Primary focus on PLSPS  Providing products and services to Pharmaceuticals and other Life Science Revenue composition (FY10) – US$813m companies  Largest Custom Research & Manufacturing service (CRAMS) provider out of Pharma & Life PLSPS India Sciences Products & 89% Agri &  Global positions in most of the key products and services we offer Services Performance APP Polymers  We work with 18 of the Top 20 Pharma companies, and 7 out of the top 10 –US$ 723m 11% - US$ 90m Agrochemical companies globally  Revenue CAGR (5yr) of 30%  Market cap ~70x in 10 years 2000-2010* FY: Fiscal year ending March 31 * Market cap of Jan 3 2000 vs Jan 4 2010 Leader in CRAMS Shareholding pattern Founded by Bhartia Group Globally no.1 in Propriet ary Pyridine and it s product s derivat ives Leading player APIs in DDDS in CRAMS India India’s largest CRAMS company – FY10 revenues US$ 458mn Among t op 3 in Drug Discovery several APIs Mkt Cap of ~ US$1.2 billion Leading player in Nort h CMO America in CMO for S t erile Inj ect ables as on March 31, 2010 Market positions sourced from Company analysis & estimates 3 3

Global Presence Corporat e Office Manufact uring Facilit ies R&D Facilit ies Int ernat ional S ubsidiaries Indian S ubsidiaries Gent, Belgium Branch Offices Kirkland, Quebec, Canada Regulat ory & Generic Market ing US FDA approved facilit y for cont ract manufact uring of S t erile inj ect ables & Non S t erile product s and RadioPharma Noida, Uttar Pradesh Shanghai, China Corporat e Office & Market ing Office R&D Cent res Spokane, Washington, USA US FDA approved facilit y for Roorkee, Uttarakhand cont ract manufact uring of S t erile UKMHRA approved facilit y for inj ect ables & Non S t erile product s generics and Allergenic Ext ract s Gajraula, Uttar Pradesh Largest int egrat ed pyridine & it s derivat ives facilit y in t he world Chittorgarh, Rajasthan Agri-Product s : S ingle S uper Phosphat e Lucknow Samlaya, Gujarat Animal Nut rit ion Product s Salisbury, Maryland, USA US FDA approved facilit y for generics Bharuch, Gujarat S EZ for Vit amins and Life Pune New Haven, Connecticut , USA S cience derivat ives Hyderabad Market ing Office Bangalore, Karnataka S t at e-of-art Discovery Cent re Ambarnath, Maharashtra Bedminster, New Jersey, USA Exclusive S ynt hesis - Pyridine Clinical Research Cent re derivat ives Nanjangud, Karnataka US FDA, AFS S APS & PDMA approval Chennai API manufact uring facilit y International sales in more than 65 countries Nira, Maharashtra Present in India, North America, Europe and China Life S ciences Chemicals 8 manufacturing facilities in India and 3 in North America Employs over 5900 people including 1100+ in R&D and 1450+ in North America Not e: This illust rat ion is not exhaust ive. This illust rat ion is not t o scale 4 4

Industry Overview 5 5